An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs KA 2507 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms HDAC6i
- Sponsors Karus Therapeutics
- 18 Sep 2017 According to a Karus Therapeutics media release, the first patient has been dosed in this trial.
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.
- 09 Jan 2017 New trial record